Coloplast to acquire wound care company Kerecis for $1.3B

Coloplast plans to acquire Kerecis and its SurgiBind fish skin wound care biologic. [Image from Kerecis]Coloplast announced today that it entered into an agreement to sign Kerecis, a developer of biologics for the wound care market.

The agreement has a total value reaching up to $1.3 billion. Of that, Coloplast intends to pay $1.2 billion in an upfront cash payment.

Denmark-based Coloplast sees Kerecis as an “attractive opportunity” to strengthen its presence in the advanced wound care market, according to a news release. The purchase would allow the company to enter the high-growth, U.S.-centric biologics segment.

Kerecis developed and patented a clinically differentiated, sustainable and scalable technology platform based on intact fish skin. It retains its similarity to human skin while production requires minimal processing. Coloplast said this results in improved wound healing. Since launching its product in 2016, Kerecis has grown quickly …

Read more
  • 0